{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:40Z","timestamp":1792007740760,"version":"4.4.0"},"reference-count":26,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: Inflammation plays an important role in cancer development, and various inflammation parameters are used as potential prognostic markers. This study aimed to evaluate the effectiveness of the combined use of HALP and H index in predicting pathological response to neoadjuvant therapy in patients with HER2-positive early-stage breast cancer. Method: This retrospective cohort study was conducted on 146 HER2-positive breast cancer patients treated in two centers. To stratify patients by their predicted probability of pathological response, HALP and H index values were combined into a composite biomarker score called the combined response score (CRS). Patients were classified into three groups based on biomarker levels: 0 = low CRS (low predictive score), 1 = intermediate CRS, and 2 = high CRS (high predictive score). These groups reflect predicted response likelihood and do not represent actual pathological outcomes. Pathological response results were evaluated according to the combined response score. Pathological complete response (pCR) was defined as residual cancer burden (RCB) 0, indicating no residual invasive tumor in breast or lymph nodes. Results: The mean age of 146 early-stage breast cancer patients included in our study was 52.3 \u00b1 11.3 (min: 29-max: 83). In the ROC analysis, the optimum cut-off value for the HALP score in pathological response classification was found to be 36 (AUC = 0.608, sensitivity = 76.29%, specificity = 44.9%, PPV = 73%, NPV = 47.89%) and 2.3 for the H index (AUC = 0.641, sensitivity = 65.98%, specificity = 51.02%, PPV = 72.73%, NPV = 43.1%). While the pathological complete response rate was 66.4% in all patients, it was 81.8% in those with a combined score of 2, 51% in those with a score of 1, and 58.6% in those with a score of 0 (p &lt; 0.001). In the logistic regression analysis, the probability of pathological response in patients in the combined score = 2 group is 3.77 times higher than in group 0. In the Fagan nomogram, the pretest probability of pathological response is 66%, while the post-test probability for combined response score group 2 is 81.5%, and for the low-H index &lt; 2.3 and the high-HALP \u2265 36 patient group, our estimate for pathological complete response increases to 82%. Conclusions: The HALP-H index combined score is an important predictor of pathological response in early-stage HER2-positive breast cancer patients, independent of histological type and stage. This new score may enable personalized approaches in treatment planning.<\/jats:p>","DOI":"10.3390\/jcm14134431","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:42:34Z","timestamp":1750664554000},"page":"4431","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer\u2014A Multicenter Retrospective Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Mustafa","family":"Seyyar","sequence":"first","affiliation":[{"name":"Departmant of Medical Oncology, Gaziantep City Hospital, Gaziantep 27100, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin Can","family":"\u015eanc\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kocaeli City Hospital, Kocaeli 41000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"K\u00f6\u015feci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, \u00c7ukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u0131l","family":"Karakayal\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kocaeli City Hospital, Kocaeli 41000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutianur \u00d6zkorkmaz","family":"Akda\u011f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-6666","authenticated-orcid":false,"given":"Yasemin Bakkal","family":"Temi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaz\u0131m","family":"Uygun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-5377","authenticated-orcid":false,"given":"Umut","family":"Kefeli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Mete","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine, \u00c7ukurova University, Adana 01250, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"\u00c7abuk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3322\/caac.21634","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2022.11.019","article-title":"Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy","volume":"180","author":"Kang","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_8","first-page":"9053","article-title":"Bibliography Current World Literature Vol 21 No 6 November 2009","volume":"105","author":"Arriola","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014A role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1177\/00031348231191200","article-title":"Influence of Prognostic Nutritional Index on the Surveillance After Surgery-Based Systematic Therapy for Breast Cancer","volume":"89","author":"Zhang","year":"2023","journal-title":"Am. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1245\/s10434-011-1814-0","article-title":"Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients","volume":"19","author":"Azab","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pang, J., Ding, N., Yin, N., and Xiao, Z. (2024). Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-57343-0"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41370","DOI":"10.18632\/oncotarget.5629","article-title":"Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: A retrospective cohort study","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shi, Y., Shen, G., Zeng, Y., Ju, M., Chen, X., He, C., Liang, L., Ge, X., Sun, X., and Di, X. (2023). Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy. Int. Immunopharmacol., 123.","DOI":"10.1016\/j.intimp.2023.110773"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/hepr.13885","article-title":"The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child-Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma","volume":"53","author":"Toshida","year":"2023","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaoto.2020.1019","article-title":"Host Factors Independently Associated with Prognosis in Patients with Oral Cavity Cancer","volume":"146","author":"Valero","year":"2020","journal-title":"JAMA Otolaryngol.\u2013Head Neck Surg."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xu, X., Zhao, W., Liu, C., Gao, Y., Chen, D., Wu, M., Li, C., Wang, X., Song, X., and Yu, J. (2024). The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy. BMC Cancer, 24.","DOI":"10.1186\/s12885-023-11719-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.05.005","article-title":"Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies","volume":"58","author":"Mei","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0148607113502674","article-title":"Prevalence of malnutrition and current use of nutrition support in patients with cancer","volume":"38","author":"Michallet","year":"2014","journal-title":"JPEN. J. Parenter. Enter. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Dong, J., Jiang, W., Zhang, W., Guo, T., Yang, Y., Jiang, X., Zheng, L., and Du, T. (2024). Exploring the J-shaped relationship between HALP score and mortality in cancer patients: A NHANES 1999-2018 cohort study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1388610"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/lio2.603","article-title":"Prognostic value of H-index in patients surgically treated for squamous cell carcinoma of the larynx","volume":"6","author":"Zanelli","year":"2021","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Xue, L.B., Liu, Y.H., Zhang, B., Yang, Y.F., Yang, D., Zhang, L.W., Jin, J., and Li, J. (2019). Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis. Medicine, 98.","DOI":"10.1097\/MD.0000000000013842"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zeng, Y., and Liu, W. (2024). The role of systemic immune-inflammation index in predicting pathological complete response of breast cancer after neoadjuvant therapy and the establishment of related predictive model. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1437140"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab with or Without Lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Prat, A., Carey, L.A., Adamo, B., Vidal, M., Tabernero, J., Cort\u00e9s, J., Parker, J.S., Perou, C.M., and Baselga, J. (2014). Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J. Natl. Cancer Inst., 106.","DOI":"10.1093\/jnci\/dju152"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4431\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:56:35Z","timestamp":1760032595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":26,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134431"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134431","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]}}}